PAPP-A in cardiac and non-cardiac conditions

详细信息    查看全文

• 作者：Yuehua Li^a ; ^b ; ^c ; Chenghui Zhou^a ; ^d ; Xianliang Zhou^a ; ^c ; ^{xlzhou-fw@hotmail.com} ; Lei Song^a ; ^b ; ^c ; ^{lsongqd@yahoo.com} ; Rutai Hui^a ; ^b ; ^c
• 关键词：Pregnancy-associated plasma protein-A ; Biomarker ; Atherosclerosis ; Cancer ; End stage renal disease
• 刊名：Clinica Chimica Acta
• 出版年：2013
• 出版时间：18 February, 2013
• 年：2013
• 卷：417
• 期：Complete
• 页码：67-72
• 全文大小：545 K

文摘

Pregnancy-associated plasma protein-A (PAPP-A), a newly discovered member of insulin like growth factors (IGFs) axis, has been reported to be a biomarker in both cardiac and non-cardiac conditions. PAPP-A mainly acts as a protease cleaving IGF inhibitors ¡ª IGF binding proteins (IGFBPs), thereby setting free IGFs. In cardiac conditions, PAPP-A plays an important role in progressive atherosclerosis. As a biomarker, PAPP-A is not only sensitive, specific and early for diagnosis of acute coronary syndrome, but also an independent risk factor for all-cause mortality or combined cardiovascular events. In non-cardiac conditions, PAPP-A is a new anti-aging target. PAPP-A knock out (KO) mice have a prolonged lifespan than the wild type. In addition, PAPP-A is also a biomarker associated with malignant cancer and end stage renal disease.